Karuna Therapeutics nabs $12 mln, raising Series B to $80 mln
Karuna Therapeutics has raised an additional $12 million for its Series B round, bringing the total to $80 million. The new investor is Sofinnova Investments. Karuna focuses on targeting muscarinic cholinergic receptors for the treatment of neuropsychiatric disorders.
1 April 2019•1 min read
